Evidence map›Paper›PMID 34093867›Full record

ArticleTheranostics2021

Nanoparticle encapsulation of non-genotoxic p53 activator Inauhzin-C for improved therapeutic efficacy.

Nimisha Bhattarai, Jieqiong Wang, Daniel Nguyen, Xiaoxiao Yang, Linh Helmers, Jennifer Paruch, Li Li, Yiwei Zhang, Kun Meng, Alun Wang and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Theranostics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 57% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Nimisha BhattaraiDepartment of Biochemistry & Molecular Biology and Cancer Center, Tulane University School of Medicine, New Orleans, LA, USA.
Jieqiong WangDepartment of Biochemistry & Molecular Biology and Cancer Center, Tulane University School of Medicine, New Orleans, LA, USA.
Daniel NguyenDepartment of Biochemistry & Molecular Biology and Cancer Center, Tulane University School of Medicine, New Orleans, LA, USA.
Xiaoxiao YangDepartment of Chemistry, Georgia State University, Atlanta, GA, USA.
Linh HelmersLaboratory of Cellular Immunology, Ochsner Clinic Foundation, New Orleans, LA 70121, USA.
Jennifer ParuchLaboratory of Cellular Immunology, Ochsner Clinic Foundation, New Orleans, LA 70121, USA.
Li LiLaboratory of Cellular Immunology, Ochsner Clinic Foundation, New Orleans, LA 70121, USA.
Yiwei ZhangDepartment of Biochemistry & Molecular Biology and Cancer Center, Tulane University School of Medicine, New Orleans, LA, USA.
Kun MengDepartment of Chemistry, Tulane University School of Science and Engineering, New Orleans, LA, USA.
Alun WangDepartment of Pathology, Tulane University School of Medicine, New Orleans, LA, USA.
Janarthanan JayawickramarajahDepartment of Chemistry, Tulane University School of Science and Engineering, New Orleans, LA, USA.
Binghe WangDepartment of Chemistry, Georgia State University, Atlanta, GA, USA.
Shelya ZengDepartment of Biochemistry & Molecular Biology and Cancer Center, Tulane University School of Medicine, New Orleans, LA, USA.
Hua LuDepartment of Biochemistry & Molecular Biology and Cancer Center, Tulane University School of Medicine, New Orleans, LA, USA.
Tulane University · USOchsner Medical Center · USGeorgia State University · US

Funding

The Role of Ribosomal Proteins in the P53-MDM2 PathwayR01CA095441 · NCI · TULANE UNIVERSITY OF LOUISIANA · PI LU, HUA · 2002 to 2021
$5.1M
Role of the AMPK-MDMX-p53 pathway in cancerR01CA127724 · NCI · TULANE UNIVERSITY OF LOUISIANA · PI LU, HUA · 2007 to 2019
$3.0M
The Role of p53-R249S’s GOF in HCC developmentR01CA234605 · NCI · TULANE UNIVERSITY OF LOUISIANA · PI LU, HUA · 2019 to 2023
$1.8M
NCI NIH HHS R01 CA095441NCI NIH HHS R01 CA127724NCI NIH HHS R01 CA234605
6 · The paper itself

Abstract

The tumor suppressor protein p53 remains in a wild type but inactive form in ~50% of all human cancers. Thus, activating it becomes an attractive approach for targeted cancer therapies. In this regard, our lab has previously discovered a small molecule, Inauhzin (INZ), as a potent p53 activator with no genotoxicity.

Indexed as

AnimalsAntineoplastic AgentsBiological AvailabilityCell Line, TumorCell MovementCell ProliferationColorectal NeoplasmsHumansIndolesLung NeoplasmsMiceMice, Inbred C57BLMicroscopy, Electron, TransmissionNanoparticlesPhenothiazinesSpectroscopy, Fourier Transform InfraredAntineoplastic AgentsinauzhinIndolesPhenothiazinesTumor Suppressor Protein p53and colorectal canceranti-cancer therapycell growthefficacyInauhzin-Clung cancernanoparticle encapsulationp53PK

Identifiers

PMID34093867
PMCPMC8171090
OpenAlexW3161833978

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.